Free tool
FAERS Monitor: Danyelza
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761171 or its brand name (Danyelza, Naxitamab-Gqgk). Reports on generic versions are filed under their own applications.
Reports
250
Serious
191
76% of reports
Hospitalization
86
Death reported
11
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hypotension66
- pain64
- hypertension33
- urticaria31
- off label use29
- pyrexia27
- rash27
- bronchospasm18
- abdominal pain17
- oxygen saturation decreased17
- hypoxia15
- tachycardia15
- cough14
- vomiting13
- anaphylactic reaction11
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 47 |
| 2022 | 47 |
| 2023 | 26 |
| 2024 | 55 |
| 2025 | 49 |
| 2026 | 23 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,909 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| bronchospasmSignal | 18 | 106.2 | 68.1 | 1,772 |
| hypoxiaSignal | 15 | 35.9 | 21.9 | 475 |
| hypotensionSignal | 66 | 27.7 | 22.5 | 1,687 |
| oxygen saturation decreasedSignal | 17 | 25.5 | 16.1 | 376 |
| anaphylactic reactionSignal | 11 | 16.8 | 9.4 | 148 |
| urticariaSignal | 31 | 15.6 | 11.2 | 411 |
| tachycardiaSignal | 15 | 14.2 | 8.7 | 172 |
| hypertensionSignal | 33 | 13.1 | 9.5 | 361 |
| painSignal | 64 | 8.8 | 7.1 | 446 |
| pyrexiaSignal | 27 | 6.6 | 4.6 | 124 |
| abdominal painSignal | 17 | 6.1 | 3.9 | 69 |
| rashSignal | 27 | 5.2 | 3.6 | 90 |
| coughSignal | 14 | 4.2 | 2.5 | 31 |
| off label useSignal | 29 | 2.8 | 2.0 | 33 |
| vomitingSignal | 13 | 2.3 | 1.4 | 9 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.